Get the Daily Brief
Latest Biotech News
Corxel raises $287M Series D — advancing oral GLP‑1 CX‑11 globally
Corxel Pharmaceuticals closed a $287 million Series D round to accelerate global development of CX‑11, a once‑daily oral GLP‑1 receptor agonist for obesity and type 2 diabetes. The round drew...
Eclipsebio acquires Terrain Bio — stitches AI RNA design into sequencing analytics
Eclipsebio completed the acquisition of Terrain Bio to enhance its end‑to‑end RNA therapeutic platform, combining Terrain’s machine‑learning RNA design capabilities with Eclipsebio’s...
Parse Biosciences and Graph Therapeutics partner — build massive immune perturbation atlas
Parse Biosciences and Graph Therapeutics announced a strategic collaboration to create a large‑scale immune perturbation atlas, combining Parse’s Gigalab single‑cell throughput with Graph’s...
10x Genomics moves into clinic — clinical collaborations and a CLIA lab on deck
10x Genomics announced clinical collaborations with Brigham & Women’s Hospital, Dana‑Farber Cancer Institute and the Cancer Research Institute and committed to building a CLIA‑certified laboratory...
Oxford Nanopore reverses P2 Solo phase‑out — support extended to end of 2030
Oxford Nanopore Technologies responded to customer backlash by extending hardware and software support for its PromethIon 2 Solo (P2 Solo) sequencer through the end of 2030, two years longer than...
Belay Diagnostics posts CSF genomic profiling validation — plans insurer billing
Belay Diagnostics published validation data for a cerebrospinal fluid (CSF) genomic profiling assay and signaled intentions to begin billing insurers in the coming months as it seeks to broaden...
FDA clears one Intellia CRISPR Phase 3 trial: study resumes after safety review
The U.S. Food and Drug Administration has lifted a clinical hold on one of Intellia Therapeutics’ two Phase 3 trials of its CRISPR/Cas9 candidate nexiguran ziclumeran (nex‑z) after a regulatory...
Alphamab’s HER2 bispecific halves progression risk – phase III shows 75% cut
Suzhou‑based Alphamab reported Phase 3 results showing its HER2 bispecific antibody anbenitamab (KN‑026) combined with chemotherapy reduced disease progression risk by about 75% in previously...
Roche’s CT‑388 posts 22.5% placebo‑adjusted weight loss: Phase 3 planned
Roche disclosed Phase 2 data showing its dual GLP‑1/GIP agonist CT‑388 produced a 22.5% placebo‑adjusted weight loss at 48 weeks in people with obesity, and announced plans to advance the asset...
TRexBio raises $50M to bankroll Treg‑activating eczema program
TRexBio announced a $50 million extension to its Series B to fund testing of TRB‑061 and other Treg‑centric programs. TRB‑061, currently in Phase 1, targets TNFR2 to activate regulatory T cells...
In vivo CAR‑T reverses liver fibrosis in MASH models — targeted FAP depletion
Mount Sinai researchers demonstrated that in vivo generation of CAR‑T cells targeting fibroblast activation protein alpha (FAP) on hepatic stellate cells significantly reduced liver fibrosis and...
nRichDx and Hamilton automate liquid biopsy extraction: integrated workflow unveiled
nRichDx and Hamilton extended their collaboration to automate the final wash and elution steps of the Revolution Plus Sample Prep System on the Hamilton Microlab STAR, creating an end‑to‑end,...
Field‑effect aware urine assay improves MRD tracking after bladder cancer surgery
Researchers from Stanford led by Maximillian Diehn reported a urine‑based minimal residual disease (MRD) approach that accounts for mutations in tumor‑adjacent urothelium—so‑called field...
FDA greenlights Life Biosciences’ first human test of cellular reprogramming therapy
The FDA has approved a first‑in‑human study by Life Biosciences to test a reprogramming gene therapy aimed at reversing cellular aging mechanisms. The initial trial will enroll a small cohort of...
Eclipsebio buys Terrain Bio — RNA design meets sequencing analytics in one platform
Eclipsebio acquired Terrain Bio to accelerate development of an end‑to‑end RNA therapeutic design, manufacturing and validation platform. The deal pairs Terrain’s machine‑learning RNA design...
Parse Biosciences and Graph Therapeutics to build massive immune perturbation atlas
Parse Biosciences and Graph Therapeutics announced a strategic partnership to create a large‑scale, functional immune perturbation atlas combining Graph’s patient‑derived disease models and active...
FDA lifts partial hold on Intellia CRISPR trials — one study cleared
The U.S. Food and Drug Administration has removed a clinical hold on one of two Phase 3 trials testing Intellia Therapeutics’ CRISPR-based therapy for transthyretin amyloidosis (ATTR). The action...
Insilico and Qilu ink $120M pact — AI fuels cardiometabolic push
Insilico Medicine and Qilu Pharmaceutical signed a collaboration worth up to $120 million to co-develop AI-enabled small molecules targeting cardiometabolic disease. The deal pairs Insilico’s...
Boehringer inks billion-euro IBD bet with Simcere — bispecific licensed
Boehringer Ingelheim struck a license and collaboration deal with China’s Simcere to develop SIM-0709, a preclinical TL1A×IL‑23p19 bispecific for inflammatory bowel disease. The agreement includes...
Roche advances obesity program — dual agonists head to Phase 3
Roche reported strong mid-stage weight‑loss data for a dual GLP‑1/GIP receptor agonist and is preparing Phase 3 studies after patients in a near‑year trial achieved clinically meaningful weight...